(Q41530938)

2 October 2017

1 reference

title

Paget's disease of bone: clinical, pathogenetic and therapeutic aspects (English)

1 reference

2 October 2017

0 references

Paget's disease of bone

1 reference

Papapoulos SE

1

1 reference

2 October 2017

publication date

1 April 1997

1 reference

Bailliere's clinical endocrinology and metabolism

2 October 2017

published in

1 reference

2 October 2017

volume

11

1 reference

2 October 2017

issue

1

1 reference

2 October 2017

page(s)

117-143

1 reference

Adverse effects of bisphosphonates. A comparative review

2 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Effects of two oral doses of alendronate in the treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Mineralisation defects with pamidronate therapy for Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Measles virus RNA detected in Paget's disease bone tissue by in situ hybridization.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Paramyxoviruses and Paget's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Evidence for secular change in Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

The management of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Long term effects of dichloromethylene diphosphonate in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Beneficial effects of aminohexane diphosphonate in patients with Paget's disease of bone resistant to sodium etidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological responses

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Pamidronate associated hallucinations

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Canine distemper virus localised in bone cells of patients with Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Ultrastructural features of the osteoclasts from Paget's disease of bone in relation to a viral aetiology.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Duration of response with oral clodronate in Paget's disease of bone.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Atypical multinucleated cells form in long-term marrow cultures from patients with Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Tiludronate therapy for Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Pamidronate disodium and possible ocular adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Therapeutic strategy in Paget's disease of bone.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Frequency and characteristics of familial aggregation of paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Serum osteocalcin in Paget's disease of bone: basal concentrations and response to bisphosphonate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Modulation of PTH-stimulated osteoclastic resorption by bisphosphonates in fetal mouse bone explants

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Paget's disease of bone and hyperparathyroidism: coincidence or causal relationship?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

A survey of respiratory syncytial virus and parainfluenza virus type 3 neutralising and immunoprecipitating antibodies in relation to Paget disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Failure to detect paramyxovirus sequences in Paget's disease of bone using the polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Osteoclast ultrastructure in Paget’s disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Detection of measles virus nucleocapsid transcripts in circulating blood cells from patients with Paget disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Ototoxicity associated with intravenous bisphosphonate administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Bisphosphonates: mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Long-lasting dermatological lesions after tiludronate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Seeking the elusive etiology of Paget disease: a progress report

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Familial aggregation of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Clinical and biochemical effects of EHDP in Paget's disease of bone: patterns of response to initial treatment and to long-term therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

Quantitative bone scintigraphy in Paget's disease treated with APD

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980553-8

7 January 2021

10.1016/S0950-351X(97)80553-8

Identifiers

DOI

1 reference

2 October 2017

1 reference